Assessment of breast cancer chemotherapy dose reduction in an integrated healthcare delivery system.

ABSTRACT:

Purpose

Most cytotoxic drugs are dosed using body surface area (BSA), yet not all cancer patients receive the full BSA-determined dose. Prior work suggests that breast cancer patients who are obese are more likely to experience dose reduction than normal weight patients. However, the factors driving dose reduction remain unclear.

Methods

In 452 women diagnosed with stage I-IIIA primary breast cancer at Kaiser Permanente Northern California, we evaluated the association between obesity and dose reduction, and further explored other factors in relation to dose reduction, including various sociodemographic characteristics, tumor characteristics, and comorbidities. Study participants were a part of the Pathways Study, diagnosed between 2006 and 2013 and treated with cyclophospha

SUBMITTER: Kantor ED 

PROVIDER: S-EPMC10885738 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature